Replies to post #86433 on Biotech Values

[turtlepower]

PARD CRC - The results continue to look good. I can't see what's new from this summer though. I'll probably get back in once they sort out their financing issues early next year.

[DewDiligence]

PARD’s 2-day rollercoaster leaves a whopping loss—multiplicative arithmetic really bites in cases like this.

Yesterday: -76% (failed trial in SCLC)
Today: +36% (“new” data in CRC)
=====
Cumulative 2-day change: -67%